One CRISPR treatment cut “bad” cholesterol in half for a full year
A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year later, with the highest dose lowering LDL by 52.5% and triglycerides by 47.8%.
The recent trial results of a CRISPR therapy that significantly lowered "bad" cholesterol in patients with difficult-to-treat lipid disorders are a promising development in the field of cardiovascular health. The fact that a single dose of the treatment was able to cut LDL cholesterol and triglycerides by about half, with sustained effects for a full year, suggests a potential game-changer for patients struggling with high cholesterol.
This breakthrough is particularly significant given the challenges of treating lipid disorders, which are a major risk factor for heart disease. Current treatments often require ongoing medication and lifestyle changes, and even then, some patients may not achieve desired cholesterol levels. The CRISPR therapy, which uses gene editing to target and modify specific genes involved in cholesterol production, offers a new approach that could potentially provide long-term benefits with minimal ongoing treatment.
As the pharmaceutical industry continues to explore the potential of gene editing therapies, it's worth watching to see how this treatment progresses through clinical trials and regulatory approvals. Key questions to consider include the safety and efficacy of the treatment in larger patient populations, potential side effects, and how it compares to existing treatments. Additionally, the cost and accessibility of the therapy will be crucial factors in determining its impact on public health.
Originally reported by sciencedaily.com. PrescriptionNews adds analysis for health & wellness readers.